StemoniX produces assay plates containing living human microOrgans®, including electrophysiologically active neural (microBrain®) and cardiac (microHeart®) cells, to enable high-throughput screening for drug discovery. Its products simplify screening workflows and the company also offers a SaaS branch that partners with organizations to screen compounds and create customized microOrgan models and assays. StemoniX raised $14.4M in a Series B financing led by Brightstone Venture Capital. Participants included initial investors Crescent Ridge Partners and SEED San Diego and new investors Alumni Ventures Group, Keshif Ventures, and Mayo Clinic. The company intends to use the funds to expand commercial operations at sites in Minnesota and California supporting its microBrain, microHeart, and Discovery as a Service offerings, and to drive development of new products and services leveraging its stem cell technologies. StemoniX is based in Maple Grove, Minnesota, and is led by co-founder and CEO Ping Yeh.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2019